Opportunities and challenges of incretins-based hypoglycemic agents treating of T2DM from the insight of physiological disposition

• DOI: 10.22541/au.170670903.33408087/v1
• Publication Date: 2024-01-31T13:50:42Z
• Authors: Yaochen Xie; Qiaojun He; Xiaoyi Wang; Jincheng Wang
• Keywords: Disposition

The treatment on patients with T2DM who suffered from defective in insulin secretion and inability of tissues responding to properly have been studied for decades. Currently, incretins-based hypoglycemic agents become a focus treating this kind drugs could be classified as GLP-1 receptor agonists which mimic the function DPP-4 antagonists avoid being degraded. Both them focused polypeptide. Since are widely used, physiological disposition is great significance discovering more effective providing guidance clinicals T2DM. In review, we summarize mechanisms these two kinds provide information currently approved. addition, each type thoroughly reviewed. By based drugs, different situation choose their physical conditions need supplementary drug interactions. We also hope some novel structure appropriate inspired invented.